A Prospective Comparative Study Involving Multiple Units to Evaluate the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupus Erythematosus.
Affiliated Hospital of Shandong University of Traditional Chinese Medicine
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age range: 18 - 65 years old;
Meets the revised SLE classification criteria of the American College of Rheumatology in 1997 or the SLE diagnostic classification criteria issued by EULAR/ACR in 2019;
The SELENA-SLEDAI score is at least 8 points (clinical symptoms are no less than 6 points, excluding positive anti-double-stranded DNA (anti-dsDNA) and low complement);
Has not responded well to hormone and/or immunosuppressant treatment, is intolerant or has recurrence, and is willing to accept tixocortinib/belimumab as a therapeutic drug.
You may not be if
Any of the following conditions exists: active central nervous system disease, severe active lupus nephritis, HIV infection, hepatitis B or C virus infection, low gamma globulinemia, liver dysfunction;
eGFR \< 30 mL/min/1.73m², or undergoing hemodialysis or kidney transplantation;
Pregnant women, or women who are about to become pregnant in the near future, or lactating women;
Participants who are simultaneously participating in other clinical studies;
Within 1 year before randomization, received B-cell targeted therapy (including belimumab);
During treatment, used traditional Chinese medicine with immunosuppressive effects (such as Tripterygium wilfordii, White Peony Root, etc.) in combination.
Clareo Health | A Prospective Comparative Study Involving Multiple Units to Evaluate the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupus Erythematosus.
